U.S., June 18 -- ClinicalTrials.gov registry received information related to the study (NCT07655427) titled 'A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SRSD107 in Healthy Chinese Subjects' on June 08.
Brief Summary: This was a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of subcutaneously administered SRSD107 in Chinese healthy subjects. SRSD107 is a synthetic, chemically modified double-stranded siRNA designed to silence hepatic FXI mRNA, thereby modulating coagulation.
Study Start Date: March 29, 2024
Study Type: INTERVENTIONAL
Condition:
Thrombus
Interventi...